The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine

Noah Craft, Kevin W. Bruhn, Bidong D. Nguyen, Robert Prins, Jia Wei Lin, Linda M. Liau, Jeffery F. Miller

研究成果: 雜誌貢獻文章同行評審

82 引文 斯高帕斯(Scopus)

摘要

Activation of innate immune cells through TLR triggers immunomodulating events that enhance cell-mediated immunity, raising the possibility that ligands to these receptors might act as adjuvants in conjunction with T cell activating vaccines. In this report, topical imiquimod, a synthetic TLR7 agonist, significantly enhanced the protective antitumor effects of a live, recombinant listeria vaccine against murine melanoma. This tumor protective effect was not dependent on direct application to the tumor and was associated with an increase in tumor-associated and splenic dendritic cells. Additionally, the combination of imiquimod treatment with prior vaccination led to development of localized vitiligo. These findings indicate that activation of the innate immune system with TLR ligands stimulates dendritic cell activity resulting in a bypass of peripheral tolerance and enhanced antitumor activity. The results of these studies have broad implications for future designs of immunotherapeutic vaccines against tumors and the treatment of metastatic melanoma.

原文英語
頁(從 - 到)1983-1990
頁數8
期刊Journal of Immunology
175
發行號3
DOIs
出版狀態已發佈 - 八月 1 2005

ASJC Scopus subject areas

  • 免疫學和過敏
  • 免疫學

指紋

深入研究「The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine」主題。共同形成了獨特的指紋。

引用此